ArticleFrontiers in cardiovascular medicine2025
Association between the TAPSE/PASP ratio and exercise capacity in heart transplant candidates with advanced heart failure.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peak oxygen consumption (VO₂) is a key determinant of heart transplant eligibility in advanced heart failure (HF), reflecting integrated cardiopulmonary performance and long-term prognosis. We aimed to evaluate the association between the tricuspid annular plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP) ratio-a non-invasive marker of right ventricular-pulmonary arterial (RV-PA) coupling-and exercise capacity, as measured by peak VO₂, in heart transplant candidates. Methods: We retrospectively analyzed 384 consecutive patients with advanced HF listed for heart transplantation between 2021 and 2023. All underwent transthoracic echocardiography, cardiopulmonary exercise testing (CPET), and right heart catheterization (RHC). Patients with LVEF >25%, severe pulmonary disease, or contraindications to CPET/RHC were excluded. Participants were stratified into tertiles by TAPSE/PASP ratio. A directed acyclic graph (DAG) guided confounder selection for multivariable linear regression assessing the association between TAPSE/PASP and peak VO₂. Cox proportional hazards models evaluated the relationship between TAPSE/PASP and a composite endpoint of death, left ventricular assist device implantation, or transplantation. Results: The mean age of the patients was 50 ± 11 years; 14% were female. Higher TAPSE/PASP tertiles were associated with longer exercise duration, higher peak VO₂, and better ventilatory efficiency. In adjusted regression analysis, TAPSE/PASP was strongly associated with peak VO₂ (effect size: 6.7; 95% CI: 5.1-8.4; Conclusion: TAPSE/PASP, beyond its role as a surrogate of RV function, is strongly associated with exercise capacity and, in secondary analyses, with long-term outcomes in advanced HF. Incorporating TAPSE/PASP into transplant evaluation protocols may enhance risk stratification and help identify patients who require closer monitoring and tailored management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.